Anlotinib can inhibit multiple targets, such as vascular endothelial growth factor receptor, platelet-derived growth factor receptor, fibroblast growth factor receptor, C-Kit, and RET genes (15, 16), and has been extensively utilized in the clinical treatment of lung cancer, soft tissue sarcoma, thyroid cancer, and other malignant tumors in China (17, 18). Here, RET is linked to thyroid cancer.